United States Patent 10,457,647 (Drug-Product/Method) Scope, Claim Structure, and Btk-Directed Patent Landscape
What does US 10,457,647 claim in scope terms?
US 10,457,647 claims a method of treating a Btk-modulated disease, where the disease is explicitly limited to chronic autoimmune urticaria. The method requires administration of a therapeutically acceptable amount of a compound of formula (I) (or a pharmaceutically acceptable salt).
The claim set is claim-1 anchored and then narrowed through dependent claims by tightening substituent definitions and, in later claims, by listing specific compound embodiments.
Core claim elements:
- Therapeutic target linkage: “modulation of Btk” (molecular target gate)
- Indication: “disease is selected from chronic autoimmune urticaria” (single indication gate)
- Therapy modality: administration of a formula (I) compound or salt (chemical gate)
- Compound structure variability: substitution rules (R groups) with multiple degrees of freedom
- Sub-structure families: azacycles (azacyclic rings) and unsaturated terminal groups (R13)
What is the claim-1 scaffold and how broad is the formula (I) coverage?
Claim 1 is a Markush-style formula definition. The breadth comes from how many R-variables are permitted to vary and how the ring options expand the number of acceptable structures.
Claim 1 key variable blocks
A. Aromatic core and halogen pattern
- R2 = fluoro
- R3 = hydrogen
- R4 = hydrogen
- R5 = fluoro
- R1 = methyl or hydroxymethyl
- R6 = H
- R7 = cyclopropyl
These enforce a fluoro/fluoro aromatic motif and a cyclopropyl substituent fixed at R7, with a small choice at R1 (methyl vs hydroxymethyl).
B. Linker/amine substituent family
- R and R′ = H (hard constraint)
- n = 0 or 1 (controls presence/absence of a structural element dependent on formula I definition)
C. Azacyclic or carbocyclic ring expansion through R8-R11
- R8, R9, R10, R11 each independently = H or C1-C6 alkyl
- Or: any two of R8-R11 together with the carbon atom they are bound to may form a 3-6 membered saturated carbocyclic ring
- Or: R12 and any one of R8, R9, R, R′, R10 or R11 together with atoms they bind to may form a 4, 5, 6 or 7 membered azacyclic ring (optional substitutions: halogen, cyano, hydroxyl, C1-C6 alkyl, C1-C6 alkoxy)
This is the main expansion lever: it allows the substituent pattern to either remain acyclic (H/C1-C6 alkyl) or to cyclize into saturated carbocycles and/or medium-ring azacycles.
D. R12 and R13 define the “functional” end groups
- R12 = hydrogen or C1-C6 alkyl, optionally substituted by halogen or C1-C6 alkoxy
- R13 = C2-C6 alkenyl optionally substituted by C1-C6 alkyl or C1-C6 alkoxy
or C2-C6 alkynyl optionally substituted by C1-C6 alkyl or C1-C6 alkoxy
So claim 1 covers vinyl/allyl-like and propargyl/alkynyl-like variants at R13 with optional substitution.
Bottom-line breadth of claim 1
Claim 1 is broad at the chemical level because:
- It fixes the Btk-relevant chemotype only at a set of anchor positions (two aryl fluorines, cyclopropyl at R7, R and R′ = H, certain hydrogens).
- It leaves multiple substitution positions flexible (R8-R11 cyclization logic, R12 optional substitution, R13 alkenyl/alkynyl options).
- It includes ring-formation options that convert an initially generic substituent set into multiple medium-ring classes.
Claim 1 remains narrow at the use level because the indication is fixed to chronic autoimmune urticaria.
How do dependent claims narrow the formula and what does that imply about prosecution strategy?
Claims 2 through 7 step down breadth by removing options:
- Claims 2, 3, 5, 6: repeatedly fix R1 = methyl or hydroxymethyl and keep R2/R5 as fluoro and R6/R7 as H/cyclopropyl.
- Claims 3 and 5 reduce variability at R8-R11 (claim 3 sets R8-R11 = H; claim 5 keeps R8-R11 = H or C1-C6 alkyl).
- Claim 4 and claim 6 introduce additional tightening around how rings form using paired variables (e.g., “R8 and R9” constraints; “R12 and any one of R10 or R11 together may form” azacycle).
Claim 7 is a further constraint set:
- R1 is C1-C6 alkyl (bigger set than claim 2/3/5)
- R8-R11 all = H
- R12 = H
- n = 0
- R13 limited to C2-C6 alkenyl (not alkynyl, from the text provided)
This pattern reads like an attempt to preserve:
- a core claim 1 for broad chemotype coverage
- multiple dependent fallbacks that cover narrower subsets of the Markush scaffold likely closer to commercial compounds or likely infringers
What are the “enumerated compound” dependent claims (claim 8 and claim 9)?
Claims 8 and 9 shift from generic formula language into explicit compound lists, each formatted as “N-(…)-…benzamide” style structures with defined stereochemistry and specific acylated linker groups (notably acrylamide/acryloyl, propiolamide/propioloyl, and but-2-enoyl/but-2-ynamido families).
Claim 8: broad enumerated set (many embodiments)
Claim 8 lists dozens of specific compounds including:
- aryl substitution: 5-fluoro-2-methylphenyl with cyclopropyl and 2-fluorobenzamide
- a pyrimidinyl core and substituted oxy-linkers into azetidine, piperidinyl, pyrrolidinyl, or isoquinolinone-linked scaffolds
- stereochemical tags: (S), (R), and (2S,4R) type pairs
- R13-like functionality appears as acrylamide/unsaturated acyl motifs (acryloyl, but-2-enoyl, propioloyl, but-2-ynoyl, and cyanation variants)
Claim 9: narrower enumerated set
Claim 9 restricts to fewer named examples, including (from the text you provided):
- the acrylamide/alkenyl and but-2-ynoyl variants
- specific stereochemistries like (S) and (2S,4R)
- fewer azetidine and pyrrolidine enumerations than claim 8
What is the functional claim linkage to “Btk modulation”?
Claim 1 requires modulation of Btk, but the provided claim text does not include:
- assay method details
- IC50/EC50 thresholds
- binding mode language
- specific Btk-related biomarkers
Practically, that means the patent is positioned as a method-of-treatment claim where Btk modulation is a functional limitation tied to the formula I compound class. The chemical definitions likely reflect the known Btk-targeted chemotype, but the text provided does not include the pharmacology thresholds.
What does the landscape look like: what is protectable here and what is left exposed?
Using only what is present in the claims provided:
- The indication is pinned to chronic autoimmune urticaria.
- The chemistry is protected as a formula I family and as named compounds in dependent claims.
- The method is not claimed as a “use of an approved drug” in your excerpt; it is claimed as administration of a formula I compound (or salt).
Key landscape implications for freedom-to-operate (FTO)
1) Indication lock creates a strong “skin” against prior art on other diseases
If prior patents claim the same Btk-modulating compounds for other indications, this patent can still be vulnerable depending on:
- whether those uses are prior art
- whether there is a pathway to obviousness/enablement for urticaria
But within claim text, the therapy use is explicitly restricted, so generic “same molecule, different disease” noninfringement/invalidity analysis becomes central.
2) The formula Markush likely overlaps with existing Btk inhibitor chemotypes
The enumerated compounds look like a benzamide-pyrimidine scaffold with:
- two aromatic fluorines
- cyclopropyl substitution
- heterocycles (azetidine/pyrrolidine/piperidine)
- unsaturated acyl/linker functionalities at a terminus
That style is consistent with Btk-directed small molecules that use polar linkers and electrophile-containing substituents.
3) Dependent enumerations suggest commercially relevant subtypes
The heavy use of:
- acrylamide/acryloyl
- propiolamide/propioloyl
- but-2-enoyl / but-2-ynoyl
- cyanopyrrolidine variants
signals that the prosecution likely wanted coverage for concrete marketed or near-term candidates within formula I.
4) Claim narrowing likely mirrors stereochemical control and R13 substitution
Dependent claims and named embodiments emphasize stereochemistry (S/R; 2S,4R etc.) and R13 geometry (alkenyl vs alkynyl). That is where design-around risk concentrates:
- if a competitor changes stereochemistry or removes the unsaturated terminus category, it may escape some dependent claim coverage but still fall into claim 1 depending on whether those options remain available.
Where are the highest-risk design-around levers inside these claims?
Based on the variable language provided, the most actionable “escape” positions for a competitor are those that are explicitly constrained:
-
R2 and R5 must both be fluoro
Changing either fluorine (or removing one) likely exits the literal scope of formula I.
-
R7 is fixed as cyclopropyl
Replacing cyclopropyl likely avoids claim coverage unless claim 1’s formula definition is interpreted broadly enough to accommodate substitutes (the excerpt does not show that flexibility).
-
R and R′ are fixed as H
Introducing substituents at those positions likely leaves claim 1.
-
R13 must be C2-C6 alkenyl or C2-C6 alkynyl with specified substitution caps
Switching to a different terminal group class (e.g., saturated groups, different ring systems, larger-than-C6 substitutions) could move outside literal scope.
-
n = 0 or 1 is permitted in claim 1, but some dependent claims fix n
Claim 1 stays broad, but dependent claims 6 (n=0) and 7 (n=0) are more vulnerable to design-around by toggling the element controlled by n.
-
Azacycle formation conditions depend on R12 and one of R8/R9/etc.
A competitor that avoids the azacycle-forming patterns may still be captured if acyclic R8-R11 patterns are allowed; but it may reduce overlap with dependent claims that assume specific cyclization.
How should you interpret the enumerated compounds list in claim 8 for landscape mapping?
For landscape work, claim 8 functions like a mini portfolio of embodiments:
- It provides exact structures that can be matched against:
- candidate pipelines
- competitor filings
- late-stage clinical assets in urticaria or related BTK-modulation areas
Because claim 8 includes both (E) labeling and multiple acyl group families, it also indicates that patent drafters treated these as distinct commercial variants that they expected third parties to make.
What does the claim set suggest about enforceability posture?
The patent combines:
- a high-level Markush formula method claim (claim 1)
- multiple dependent narrowing steps (claims 2-7)
- explicit enumerated embodiments (claims 8-9)
That mix is typical of enforceability strategy:
- claim 1 tries to catch “close” variants
- dependents capture “near-identical” embodiments
- enumerations offer clearer comparison points for infringement assessments
Key Takeaways
- US 10,457,647 is a Btk-modulation method-of-treatment patent with the indication fixed to chronic autoimmune urticaria and the therapy requiring a formula (I) benzamide/pyrimidine chemotype (or salt).
- Claim 1 is broad chemically through multiple variable R groups and ring-formation options (carbocycle or azacycle formation via R8-R12 logic) while remaining narrow on indication.
- Claims 2-7 carve out narrower structural subsets by fixing R1, R8-R11, ring formation conditions, and limiting n and R13 classes (alkenyl vs alkynyl).
- Claims 8-9 list specific stereodefined compounds with acryloyl/but-2-enoyl and propioloyl/but-2-ynoyl-like terminal groups, plus cyanopyrrolidine and other defined motifs, turning the patent into a concrete infringement map.
- The main design-around levers are likely fluorine pattern (R2/R5), cyclopropyl at R7, R/R′ fixed as H, and R13 terminal group class.
FAQs
1) Is US 10,457,647 a composition-of-matter patent or a method-of-treatment patent?
It is a method-of-treatment claim: it requires administration of a formula (I) compound for treating chronic autoimmune urticaria via Btk modulation (claim language you provided).
2) Does the patent cover chronic autoimmune urticaria only, or other diseases too?
The excerpted claim 1 restricts the disease to “chronic autoimmune urticaria.” It does not present additional indications in the claim text provided.
3) What structural element appears essential across the claims?
The scaffold repeatedly requires fluoro at two positions (R2 and R5) and cyclopropyl at R7, with R and R′ set to H.
4) Do dependent claims cover both alkenyl and alkynyl variants at R13?
Claim 1 allows alkenyl or alkynyl at R13, while some dependent claims (notably claim 7 as written) restrict R13 to alkenyl.
5) Why do claims 8 and 9 matter for competitors and investors?
They enumerate specific compound embodiments with detailed stereochemistry and terminal unsaturated functionalities, enabling faster cross-checking of competitor structures against literal claim coverage.
References
- United States Patent 10,457,647. (Claims text as provided in prompt: methods of treating chronic autoimmune urticaria via Btk modulation; formula (I) compound definitions; dependent claim embodiments including enumerated structures).
